Culture - Parabilis Medicines

Culture

Building something extraordinary

We are a team of passionate pioneers and life-long learners who are trailblazing the future of precision medicine. The research and therapies we’re advancing represent a unique opportunity to fundamentally change treatment paradigms for cancer and other serious diseases, and therefore to impact countless people’s lives around the world.

We approach our work with passion, humility and awe. From our drive to develop transformative medicines, to the way we interact with each other and in our communities, we are a team that comes together in expected and unexpected ways, united by a shared purpose to make a difference.

The people that make Parabilis

“After college, I coordinated clinical trials during the early days of DNA sequencing technology. This ground-breaking technology, combined with my experience working with patients, inspired me to pursue computational biology and work with scientists here who are pushing the boundaries for new treatments.”
David Ballard, Ph.D. Senior Director of Data Science

“I’m driven by the opportunity to create real value for patients through breakthrough treatments fueled by collaborations that harness the power of science to make a meaningful impact.”
Sonia Parekh Associate Director of Business Development and Alliance Management

“I am excited to be part of developing Helicon medicines that can be rapidly optimized into the ideal chemical space while precisely targeting a wide range of protein-protein and protein-DNA interactions.”
Santosh Choudary, Ph.D. Associate Director, De Novo Discovery

“Our science is groundbreaking, and our mission is inspiring, but I think it’s our team that really sets us apart. The dedication and camaraderie I see every day motivates me to be the best version of myself.”
Tara Travaline Scientist I

We see the tremendous opportunity for impact and are driven by the incredible responsibility to make it happen

Our core values

They’re not merely words on a slide — our core values are the essence of Parabilis’s culture, which we weave into the everyday scientific, clinical and business activities of the company and into how we approach each of our roles.

Growth-Minded

We’re inventing a new class of medicines — one applicable to therapeutic targets that have been dreamt about, but always considered impossible to drug. Our work requires us to be curious, humble and adaptable.

In(ter)dependent

We are fiercely independent as a leader in defying the limitations of current therapeutic modalities, and interdependent as a team as we work collaboratively to shift drug discovery paradigms and provide patients with better treatment options.

Patient-Focused

We are deeply focused on patient outcomes, and all energy in the company is focused on translating science to patient impact.

All-In

We’re fully dedicated to solving some of the hardest scientific challenges and delivering one of the most effective new classes of drugs in history.

Parabilis at work and at play

Our passion for creativity and love of learning mean growth and opportunities flourish at Parabilis! To keep up with our updates, follow us on LinkedIn.

Today, on International Day of Women and Girls in Science, we celebrate the women in Research and Development at Parabilis who are driving our progress toward CreatingExtraordinaryMedicines.

Hear from some of the incredible women on our team about what inspires them to push the boundaries of what’s possible in science and medicine.

View Post

Hot off the press at JPM25! Today Parabilis CEO Mathai Mammen, M.D., Ph.D. presented updates on the clinical progress of our β-catenin:TCF4 inhibitor, FOG-001, and our wider Helicon portfolio.

Early clinical data on FOG-001 (the first and only direct inhibitor of β-catenin:TCF4) demonstrate monotherapy antitumor activity and in-tumor target engagement — confirming Helicons’ ability to target proteins previously considered undruggable in patients.

View Post

Photo of Parabilis team playing pickleball at the 2024 Winter Outing offsite

This holiday season, Parabilis served up fun and a little friendly competition at our annual winter outing and holiday celebration, which included a spirited pickleball tournament with 36 teams, new branded swag to ring in the new year, and plenty of opportunities to come together as a team.

View Post

To celebrate our new name and vision as a company, we created pocket-sized images personifying Parabilis’ spirit and values and asked our team to take one along on their next adventure.

Over the next few weeks, employees snapped photos of their Parabilis “spaceships” while traveling to Istanbul, Penn State Stadium, Nevada mountains, Munich Hofbräuhaus, Barcelona, Turks and Caicos, Montreal, Jamaica, the Palace Theater in Ohio, Brooklyn Bridge, and outer space (or as close as we could get).

View Post

We’re thrilled to share that Parabilis Medicines has been named the winner in the Late-Stage Biotech category at the 2024 BostInno Fire Awards!

We’re immensely honored to represent the innovative spark that powers the Boston-area biotech ecosystem. 2024 has been an incredible year for us, from the growth of our team, progressing our programs forward, our Series E financing and a radiopharmaceutical collaboration to the advances in our data science-enabled platform.

View Post

Mohammed AlQuraishi presenting to Parabilis Medicines team

We were thrilled to recently welcome Mohammed AlQuraishi from Columbia University to Parabilis for a discussion about the state of the art in computational protein design today. Dr. AlQuraishi is a world expert in systems biology who recently played a central role in the development of OpenFold, an open-source AI model for predicting the 3D structures of proteins from their sequences.

View Post

Photo of Parabilis team volunteering at Hope Lodge

We’re developing medicines to address the most pressing needs in cancer treatment today. But we know that individuals and families face many kinds of hardship after a cancer diagnosis that extend far beyond the hospital or clinic: disruption to daily life, feelings of isolation, and logistical and financial burdens from treatment and care. For that reason, we felt honored recently to volunteer at the American Cancer Society Hope Lodge in Boston, a place that offers cancer patients and their caregivers a free ‘home away from home’ during their treatment.

View Post

We were honored to host Eric Schadt, a leading figure in computational biology and precision medicine, at our offices recently. In his current roles as CSO of Pathos, Dean for Precision Medicine at the Icahn School of Medicine at Mount Sinai, and across the rest of his distinguished career, Dr. Schadt has driven innovation in the use of data science to pair precise patient populations with more targeted interventions — something we’re passionately advancing here at FogPharma as well.

View Post

Photo of Parabilis team members at the Halloween and Fall Celebration

This week, TeamParabilis came together for our Haunted Fall Carnival, an afternoon filled with festive treats and carnival games, like Halloween Bingo and a spirited team relay. Whether at work or at play, our team brings their all – especially when a costume contest is involved.

View Post

We were very grateful to have Regina Barzilay — one of the world’s leading AI/machine learning researchers and a Distinguished Professor for AI and Health at CSAIL MIT — join us recently to discuss the fast-evolving landscape of machine learning in drug discovery. Dr. Barzilay presented some of her own pioneering work in building AI models to optimize small-molecule drug design and protein engineering.

View Post

Explore opportunities to join our team

Careers